Physician
Alvarez Diaz Pediatrics Corp
Alvarez Diaz Pediatrics Corp was paid $4.27M by Medicaid between Dec 2018 and Oct 2024, across 99 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 41% of everything it billed.
33Billing provider infoALVAREZ DIAZ PEDIATRICS CORP
MIAMI, FL 33155
MIAMI, FL 33155
33aNPI1679006761assigned 04/06/2017
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$4.27M
24GClaims110,598
24DCodes billed99
24AFirst – last monthDec 2018 – Oct 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Florida
Rank by total paid#3 of 56
Median peer was paid$221K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 318 | $14K | |
| 2019 | 3,677 | $214K | |
| 2020 | 6,821 | $387K | |
| 2021 | 27,987 | $579K | |
| 2022 | 27,441 | $1.19M | |
| 2023 | 30,411 | $1.24M | |
| 2024incomplete | 13,943 | $642K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 41% | 16,564 | 12,422 | $1.77M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 14,333 | 10,046 | $837K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 11% | 2,744 | 2,476 | $461K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.6% | 2,860 | 2,423 | $325K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.4% | 6,977 | 5,857 | $189K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 3,023 | 2,210 | $90K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.0% | 930 | 802 | $87K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.6% | 2,304 | 2,123 | $67K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 12,150 | 5,077 | $62K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.1% | 241 | 208 | $46K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 229 | 214 | $29K |
| 99381 | <1% | 261 | 238 | $28K |
87 more codes
| 99382 | <1% | 145 | $24K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,000 | $22K |
| 92587 | <1% | 3,887 | $22K | |
| 99383 | <1% | 114 | $21K | |
| 99188 | <1% | 3,496 | $18K | |
| 90461 | <1% | 780 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,573 | $16K |
| 99401 | <1% | 904 | $15K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,226 | $13K |
| 92552 | <1% | 538 | $12K | |
| 87807 | <1% | 2,719 | $11K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,399 | $11K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 843 | $8K |
| 83655 | <1% | 1,838 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 109 | $7K |
| 97803 | <1% | 672 | $7K | |
| 90671 | <1% | 219 | $7K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 592 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,222 | $5K |
| H0049 | Alcohol and/or drug screening | <1% | 684 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 787 | $4K |
| 90670 | <1% | 762 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 586 | $3K |
| 85018 | <1% | 2,805 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 438 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 576 | $1K |
| 0111A | <1% | 218 | $1K | |
| 99174 | <1% | 1,218 | $900.73 | |
| 86328 | <1% | 508 | $765.21 | |
| 90686 | <1% | 2,205 | $714.59 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 254 | $700.61 |
| 90680 | <1% | 789 | $677.00 | |
| 87070 | <1% | 572 | $627.38 | |
| 90651 | <1% | 147 | $530.94 | |
| 96381 | <1% | 34 | $424.92 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,678 | $406.92 |
| 90633 | <1% | 728 | $365.49 | |
| 94664 | <1% | 175 | $353.03 | |
| 99000 | <1% | 945 | $314.19 | |
| 81002 | <1% | 512 | $278.96 | |
| 0071A | <1% | 22 | $200.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 163 | $185.00 |
| 87081 | <1% | 37 | $182.79 | |
| 96127 | <1% | 95 | $129.36 | |
| 92567 | <1% | 15 | $86.95 | |
| 90380 | <1% | 15 | $80.00 | |
| 90656 | <1% | 12 | $76.00 | |
| 94760 | <1% | 66 | $65.34 | |
| 90474 | <1% | 54 | $60.00 | |
| 0072A | <1% | 31 | $40.00 | |
| 90697 | <1% | 687 | $35.72 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 43 | $23.14 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 14 | $20.00 |
| 87400 | <1% | 142 | $18.79 | |
| A4616 | Tubing (oxygen), per foot | <1% | 44 | $14.70 |
| 99050 | <1% | 17 | $7.57 | |
| 90677 | <1% | 195 | $4.00 | |
| 99173 | <1% | 178 | $2.97 | |
| G8710 | Patient prescribed antibiotic | <1% | 148 | $1.50 |
| 90619 | <1% | 12 | $1.20 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 25 | $0.12 |
| 91307 | <1% | 18 | $0.04 | |
| G8711 | Prescribed antibiotic on or within 3 days after the episode date | 0% | 539 | $0.00 |
| 90716 | 0% | 206 | $0.00 | |
| 36416 | 0% | 24 | $0.00 | |
| A9900 | Miscellaneous dme supply, accessory, and/or service component of another hcpcs code | 0% | 103 | $0.00 |
| 97802 | 0% | 93 | $0.00 | |
| 99058 | 0% | 23 | $0.00 | |
| 87088 | 0% | 20 | $0.00 | |
| 90723 | 0% | 45 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 65 | $0.00 |
| J3490 | Unclassified drugs | 0% | 12 | $0.00 |
| 92551 | 0% | 15 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 24 | $0.00 |
| 91311 | 0% | 195 | $0.00 | |
| 90700 | 0% | 28 | $0.00 | |
| 90707 | 0% | 53 | $0.00 | |
| 90685 | 0% | 33 | $0.00 | |
| 99177 | 0% | 14 | $0.00 | |
| 90648 | 0% | 149 | $0.00 | |
| 69210 | 0% | 43 | $0.00 | |
| 90715 | 0% | 33 | $0.00 | |
| 99072 | 0% | 203 | $0.00 | |
| 90713 | 0% | 74 | $0.00 | |
| 86318 | 0% | 14 | $0.00 | |
| 90710 | 0% | 13 | $0.00 | |
| 99051 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALVAREZ DIAZ, RAMIRO (PRESIDENT)